ArticleInvestigational new drugs2022
A comprehensive analysis of the microbiota composition and host driver gene mutations in colorectal cancer.
Article in Investigational new drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Fecal Microbiome Alterations in Colorectal Cancer: A Systematic Review of Compositional Changes and Microbial Biomarkers.MicrobiologyOpen · 2026Pooled it
- Strawberry dietary intervention influences diversity and increases abundances of SCFA-producing bacteria in healthy elderly people.Microbiology spectrum · 2025Trial
- Host-microbe interaction networks revealed through gut microbiota and microRNA correlation analysis in mouse models of chronic colitis and colitis-associated cancer.Journal of translational medicine · 2026Article
- Megasphaera Elesdenii Dysregulates Colon Epithelial Homeostasis, Aggravates Colitis-Associated Tumorigenesis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- SMAD4 mutation drives gut microbiome shifts toward tumor progression in colorectal cancer.Discover oncology · 2025Article
- Article
- Gut microbiota influences colorectal cancer through immune cell interactions: a Mendelian randomization study.Discover oncology · 2025Article
- Colorectal cancer in Lynch syndrome families: consequences of gene germline mutations and the gut microbiota.Orphanet journal of rare diseases · 2025Observational
- Gut microbiome signature in response to neoadjuvant chemoradiotherapy in patients with rectal cancer.Frontiers in microbiology · 2025Article
- Gut microbiota and colorectal cancer: mechanistic insights, diagnostic advances, and microbiome-based therapeutic strategies.Frontiers in microbiology · 2025Review
- Fecal microbiota is associated with extraintestinal manifestations in inflammatory bowel disease.Annals of medicine · 2024Article
- Increased abundance ofOncology letters · 2024Article
- Identification of KRAS mutation-associated gut microbiota in colorectal cancer and construction of predictive machine learning model.Microbiology spectrum · 2024Article
- Pharmacomicrobiomics in precision cancer therapy: bench to bedside.Frontiers in immunology · 2024Review
- Fecal microbial biomarkers combined with multi-target stool DNA test improve diagnostic accuracy for colorectal cancer.World journal of gastrointestinal oncology · 2023Article
- Combination of multiple omics techniques for a personalized therapy or treatment selection.Frontiers in immunology · 2023Review
- Diagnosis and functional prediction of microbial markers in tumor tissues of sporadic colorectal cancer patients associated with the MLH1 protein phenotype.Frontiers in oncology · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Studies of both, microbiota and target therapy associated with gene mutations in colorectal cancer, (CRC) have attracted increasing attention. However, only a few of them analyzed the combined effects on CRC. we analyzed differences in intestinal microbiota of 44 colorectal cancer patients and 20 healthy controls (HC) using 16S rRNA gene sequencing of fecal samples. For 39 of the CRC patients, targeted Next Generation Sequencing (NGS) was carried out at formalin fixed paraffin embedded (FFPE) samples to identify somatic mutation profiles. Compared to the HC group, the microbial diversity of CRC patients was significantly lower. In the CRC group, we found a microbiome that was significantly enriched for strains of Bifidobacterium, Bacteroides, and Megasphaera whereas in the HC group the abundance of Collinsella, Faecalibacterium, and Agathobacter strains was higher. Among the mutations detected in the CRC group, the APC gene had the highest mutation rate (77%, 30/39). We found that the KRAS mutant type was closely associated with Faecalibacterium, Roseburia, Megamonas, Lachnoclostridium, and Harryflintia. Notably, Spearman correlation analysis showed that KRAS mutations were negatively correlated with the existence of Bifidobacterium and positively correlated with Faecalibacterium. By employing 16S rRNA gene sequencing, we identified more unique features of microbiota profiles in CRC patients. For the first time, our study showed that gene mutations could directly be linked to the microbiota composition of CRC patients. We hypothesize that the effect of a targeted colorectal cancer therapy is also closely related to the colorectal flora, however, this requires further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.